Please assess the completion status of the following clinical trial:

Trial Title: Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must have relapsed or refractory acute lymphoblastic leukemia or lymphoma (ALL):~  * Stratum I: T-cell lymphoblastic leukemia or lymphoma in first relapse or refractory to one or two courses of frontline induction therapy.~ * Stratum II: B-cell or T-cell lymphoblastic leukemia or lymphoma in second or third relapse or refractory to 2 or 3 induction or re-induction attempts. Patients with Ph+ ALL must be refractory or relapsed after treatment with regimen that included a tyrosine kinase inhibitor (TKI).~* Relapse in ALL is defined as the reappearance (in a patient who has previously achieved remission) of leukemic blasts in the bone marrow.~  * Should flow cytometric analyses suggest relapse (by the reappearance of a similar immunophenotype to the original leukemia) in the presence of \<5% blasts morphologically, a repeat bone marrow test is recommended to confirm relapse.~ * Molecular or genetic relapse is characterized by the reappearance of a cytogenetic or molecular abnormality.~* Age is ≤ 21 years (participant has not yet reached 22nd birthday).~* Able to swallow capsules.~* Karnofsky or Lansky performance score is ≥ 60%. The Lansky performance score should be used for participants \< 16 years and the Karnofsky performance score for participants ≥ 16 years.~* Prior therapy:~  * There is no waiting period for participants who relapse while receiving therapy if they are free from side effects attributable to such therapy.~ * Emergent radiation therapy, one dose of intrathecal chemotherapy and up to 7 days of steroids or hydroxyurea are permitted before start of treatment in participants who relapse after completion of frontline therapy. Other circumstances must be cleared by PI or medical designee.~ * At least 90 days have elapsed since bone marrow transplant and participant is off immune suppression for ≥ 2 weeks, if applicable.~* Adequate renal function defined as glomerular filtration rate ≥ 60 cc/min/1.73m\^2 or serum creatinine based on age as follows:~  * If age is 1 to 2 years, then maximum serum creatinine (mg/dL) is 0.6 for males or females.~ * If age is 2 to 6 years, then maximum serum creatinine (mg/dL) is 0.8 for males or females.~ * If age is 6 to 10 years, then maximum serum creatinine (mg/dL) is 1 for males or females.~ * If age is 10 to \<13 years, then maximum serum creatinine (mg/dL) is 1.2 for males or females.~ * If age is 13 to 16 years, then maximum serum creatinine (mg/dl) is 1.5 for males or 1.4 for females.~ * If age is \> 16 years, then maximum serum creatinine (mg/dl) is 1.7 for males or 1.4 for females.~* Adequate hepatic function defined as:~  * Direct bilirubin ≤ 1.4 mg/dL (if total bilirubin \> 1.4 mg/dL) AND~ * AST and ALT \< 5 x ULN for age.~* Adequate cardiac function defined as shortening fraction of ≥ 27% or ejection fraction ≥ 45%.~* Lymphoma participants without bone marrow involvement must have:~  * Absolute neutrophil count (ANC) \>1,000/mm3, AND~ * Platelet count ≥50,000/mm\^3 (without transfusion support)~ * NOTE: These criteria are waived for participants with leukemia or lymphoma participants with bone marrow involvement.~* Written, informed consent and assent following Institutional Review Board, NCI, FDA and OHRP guidelines.~Exclusion Criteria:~* Prior histone deacytylases (HDAC), DAC, HSP90 inhibitors or valproic acid for treatment of cancer.~* Patients who will need valproic acid for any medical condition during the study or within 5 days prior to first panobinostat treatment.~* Impaired cardiac function or clinically significant cardiac diseases, history of arrhythmia (including ventricular fibrillation or torsade de pointes), bradycardia \<50 bpm, screening ECG with prolonged QTc or uncontrolled hypertension.~* Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat.~* Patients with diarrhea \> CTCAE grade 2.~* Other concurrent severe and/or uncontrolled medical conditions (e.g., uncontrolled diabetes or active or uncontrolled infection) including abnormal laboratory values, that could cause unacceptable safety risks or compromise compliance with the protocol.~* Patients using medications that have a relative risk of prolonging the QT interval or inducing torsade de pointes if treatment cannot be discontinued or switched to a different medication prior to starting treatment.~* Patients who have received targeted agents within 2 weeks or within 5 half-lives of the agent and active metabolites (whichever is longer) and who have not recovered from side effects of those therapies.~* Patients who have undergone major surgery ≤ 4 weeks prior to starting treatment or who have not recovered from side effects of such therapy.~* Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis B/C.~* Inability to swallow capsules.~* Active, uncontrolled infection or severe concurrent medical disease, including but not limited to congestive heart failure, cardiac arrhythmias, or psychiatric illness.~* Isolated extramedullary relapse (leukemia) or isolated CNS lymphoma.~* Pregnant or lactating (female participant of childbearing potential must have negative serum or urine pregnancy test required within 7 days prior to start of treatment). Male or female of reproductive potential has agreed to use effective contraception method for duration of study treatment.~* Down syndrome.~* Inability or unwillingness or research participant or legal guardian/representative to give written informed consent.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Study Participants (Type: EXPERIMENTAL): Participants with ALL will receive the following interventions in three treatment blocks:~* Block A: Dexamethasone, panobinostat, liposomal vincristine, mitoxantrone, peg-asparaginase, bortezomib, intrathecal triples.~* Block B: High-dose methotrexate, 6-mercaptopurine, intrathecal triples, high-dose cytarabine.~* Block C: Nelarabine or clofarabine, cyclophosphamide, etoposide.

Based on this trial design, predict the completion outcome and termination type (if applicable).